Our Team

COMPANY LEADERSHIP AND SCIENTIFIC FOUNDERS



Elisa Romeo, Ph.D.
Vice President, Research and Development

Elisa Romeo joined Gensignia as Senior Director, Research and Development in August 2013. Prior to this appointment, Dr. Romeo was Principal Scientist and then Manager, in vitro Diagnostics (IVD) Development at Pathway Genomics, where she was responsible for developing genotyping assays, the implementation of the Quality System Regulations (QSR) and the preparation and filing of regulatory submissions to the US Food and Drug Administration (FDA). Previously Dr. Romeo was the Associate Director of Assay Development and Operations at HistoRx, Inc. In that role, she led the development of new biomarkers for various BioPharma companies’ clinical trials using the Automated Quantitative Analysis (AQUATM) Technology.

Earlier, Dr. Romeo held various positions at Genoptix Medical Laboratories, a Novartis Company, developing molecular and cell-based diagnostic, prognostic and predictive assays for the Clinical Laboratory (CLIA/CAP) on blood, bone marrow and formalin-fixed paraffin embedded sample types and utilizing a wide range of technologies including quantitative real-time PCR, sequencing, allele-specific PCR (mutation detection), flow cytometry, and the AQUA technology.

Dr. Romeo earned her Ph.D. in Human Physiology from the University of Zurich, Switzerland. She also holds a Master’s Degree in Molecular Biology and Biochemistry from the University of Insubria, Italy.

Gabriella Sozzi, Ph.D.
Scientific Founder

Professor, Head of Cancer Genomics
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Mattia Boeri, Ph.D.
Scientific Founder

Principal Scientist, Cancer Genomics
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Ugo Pastorino, M.D.
Scientific Founder

Head of  Thoracic Surgery Unit
Chairman of Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

BOARD OF DIRECTORS

Gabriele Cerrone
Co-Founder & Director

Mr. Gabriele Cerrone is the Co-Founder and Director of Gensignia, which he founded in 2011. Mr. Cerrone has a successful track record and extensive experience in the commercialization of biotechnology.  Mr. Cerrone is also the Founder and Chairman of BioVitas Capital, which specializes in starting, financing and restructuring micro-cap and early-stage biotechnology or pharmaceutical products, projects and companies. He is also currently the Chairman and Founder of Tiziana Life Sciences plc, as well as Chairman and Co-Founder of Arna Therapeutics.

Mr. Cerrone co-founded Trovagene, a molecular diagnostic company and served as its Co-Chairman, was a co-founder and served as Chairman of both Synergy Pharmaceuticals and Callisto Pharmaceuticals, and was a Director of and led the restructuring of Siga Technologies. Mr. Cerrone also co-founded FermaVir Pharmaceuticals and in the past served as Chairman of the Board until its merger in September 2007 with Inhibitex. Mr. Cerrone served as a director of Inhibitex until its sale to Bristol Myers Squibb in 2012.

Gary Jacob, Ph.D.
Chairman of the Board

Dr. Gary Jacob has served as President & Chief Executive Officer and a Director of Synergy Pharmaceuticals Inc. since 2008 and as Chairman since 2013. Since 2013, Dr. Jacob has also been serving as Chairman of ContraVir Pharmaceuticals, Inc., a biopharmaceutical drug development company and was Chief Executive Officer of ContraVir from 2013 to 2014.  

Dr. Jacob currently serves as a director of Trovagene, Inc., a diagnostics company. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from 2003 until 2013 and a director from 2004 until 2013. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development.

Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.

Thomas Adams, Ph.D.

Dr. Thomas Adams is the Chairman of the Board of Trovagene, Inc. and also serves as a director of Synergy Pharmaceuticals Inc. and Xifin, Inc.  Dr. Adams has served as a director of IRIS International, Inc., a diagnostics company and was Chief Technology Officer of IRIS from 2006 until 2012 when it was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to 2006, when Leucadia was acquired by IRIS.

In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Before founding Gen-Probe, Dr. Adams held management positions at Technicon Instruments and the Hyland Division of Baxter Travenol. He has significant public-company experience serving as a director of Biosite Diagnostics, Inc., a publicly held medical research firm, from 1989 to 1998 and as a director of Invitrogen, a publicly held company. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.

John Brancaccio, C.P.A.

Mr. John Brancaccio, a retired CPA, serves as director of Trovagene, Inc., Synergy Pharmaceuticals Inc., ContraVir Pharmaceuticals, Inc. and Tamir Biotechnology. 
Since 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies.

From 2002 until 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company.

Kunwar Shailubhai, Ph.D., MBA

Dr. Kunwar Shailubhai has served as the Chief Scientific Officer of Synergy Pharmaceuticals Inc. since 2008. From 2003 until 2008 he served as Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals, Inc.  From 2003 until 2004, Dr. Shailubhai served as Executive Vice President, Research and Development of Synergy DE.

From 2001 to 2003, Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy Pharmaceuticals, Inc. where he was responsible for the preclinical development of Synergy's GC-C agonist program for drugs to treat colon cancer and GI disorders and diseases. Between 1993 and 2000, he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group.


Dr. Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his M.B.A. from the University of Missouri, St. Louis.

 


Leadership

Elisa Romeo, Ph.D.
Vice President, R&D
 

Scientific Founders

Gabriella Sozzi, Ph.D.

Scientific Founder

Mattia Boeri, Ph.D.
Scientific Founder

Ugo Pastorino, M.D.
Scientific Founder
 

Board of Directors

Gabriele Cerrone
Co-Founder of Gensignia

Gary Jacob, Ph.D.
Chairman of the Board

Thomas Adams, Ph.D.

Mattia Boeri, Ph.D.


John Brancaccio, C.P.A.


Kunwar Shailubhai, Ph.D., MBA

Riccardo Dalla-Favera, M.D.